Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of
Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy
with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for
autologous transplantation (ASCT)